SMT201600143B - Metodo di trattamento di disturbi proliferativi e altre condizioni patologiche mediate dalla attività chinasica di bcr-abl, c-kit, ddr1, ddr2 o pdgf-r - Google Patents

Metodo di trattamento di disturbi proliferativi e altre condizioni patologiche mediate dalla attività chinasica di bcr-abl, c-kit, ddr1, ddr2 o pdgf-r

Info

Publication number
SMT201600143B
SMT201600143B SM201600143T SM201600143T SMT201600143B SM T201600143 B SMT201600143 B SM T201600143B SM 201600143 T SM201600143 T SM 201600143T SM 201600143 T SM201600143 T SM 201600143T SM T201600143 B SMT201600143 B SM T201600143B
Authority
SM
San Marino
Prior art keywords
kinasic
ddr1
ddr2
bcr
abl
Prior art date
Application number
SM201600143T
Other languages
English (en)
Inventor
Neil Gallagher
Ophelia Yin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43513643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201600143(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SMT201600143B publication Critical patent/SMT201600143B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SM201600143T 2009-11-17 2016-05-23 Metodo di trattamento di disturbi proliferativi e altre condizioni patologiche mediate dalla attività chinasica di bcr-abl, c-kit, ddr1, ddr2 o pdgf-r SMT201600143B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26181209P 2009-11-17 2009-11-17
PCT/US2010/056926 WO2011062927A1 (en) 2009-11-17 2010-11-17 Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity

Publications (1)

Publication Number Publication Date
SMT201600143B true SMT201600143B (it) 2016-07-01

Family

ID=43513643

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201600143T SMT201600143B (it) 2009-11-17 2016-05-23 Metodo di trattamento di disturbi proliferativi e altre condizioni patologiche mediate dalla attività chinasica di bcr-abl, c-kit, ddr1, ddr2 o pdgf-r

Country Status (37)

Country Link
US (1) US9061029B2 (it)
EP (1) EP2501384B2 (it)
JP (2) JP5829615B2 (it)
KR (1) KR101743315B1 (it)
CN (1) CN102612368B (it)
AR (1) AR079029A1 (it)
AU (1) AU2010322102B2 (it)
BR (1) BR112012011693A2 (it)
CA (1) CA2779490C (it)
CL (1) CL2012001270A1 (it)
CO (1) CO6551690A2 (it)
DK (1) DK2501384T4 (it)
EC (1) ECSP12011903A (it)
ES (1) ES2572128T5 (it)
FI (1) FI2501384T4 (it)
GT (1) GT201200150A (it)
HK (1) HK1169950A1 (it)
HR (1) HRP20160472T4 (it)
HU (1) HUE027307T2 (it)
IL (1) IL219727A (it)
JO (1) JO3634B1 (it)
MA (1) MA33738B1 (it)
ME (1) ME02413B (it)
MX (1) MX2012005694A (it)
MY (1) MY169956A (it)
NZ (1) NZ599968A (it)
PE (1) PE20121476A1 (it)
PL (1) PL2501384T5 (it)
RS (1) RS54747B2 (it)
RU (1) RU2625835C2 (it)
SG (1) SG10201501169VA (it)
SI (1) SI2501384T2 (it)
SM (1) SMT201600143B (it)
TN (1) TN2012000206A1 (it)
TW (1) TWI498116B (it)
WO (1) WO2011062927A1 (it)
ZA (1) ZA201203328B (it)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2776130A1 (en) 2011-11-07 2014-09-17 Institut National de la Sante et de la Recherche Medicale (INSERM) A ddr1 antagonist or an inhibitor of ddr1 gene expression for use in the prevention or treatment of crescentic glomerulonephritis
AR090835A1 (es) * 2012-04-24 2014-12-10 Chugai Pharmaceutical Co Ltd Derivados de quinazolindiona
CN104379560A (zh) 2012-04-24 2015-02-25 中外制药株式会社 苯甲酰胺衍生物
CA2911040C (en) 2012-05-02 2021-11-16 Georgetown University Treating an .alpha.-synucleinopathy with tyrosine kinase inhibitors
JP6078639B2 (ja) * 2012-05-15 2017-02-08 ノバルティス アーゲー Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体
US20140080772A1 (en) * 2012-09-06 2014-03-20 The Board Of Regents Of The University Of Texas System Treatments for melanoma
US9561245B2 (en) 2012-09-06 2017-02-07 The Board Of Regents Of The University Of Texas System Combination treatments for melanoma
US9572828B2 (en) 2013-07-18 2017-02-21 The Board Of Regents Of The University Of Texas System Treatment for melanoma
AU2014338070A1 (en) 2013-10-23 2016-05-05 Chugai Seiyaku Kabushiki Kaisha Quinazolinone and isoquinolinone derivative
BR112018002118A2 (pt) * 2015-08-31 2018-09-18 Toray Industries, Inc. ?derivado de ureia, e, inibidor de receptor de domínio de discoidina 1?
CN108103186B (zh) * 2018-02-28 2021-07-02 固安博健生物技术有限公司 诊断类风湿性关节炎和骨关节炎的分子标志物
EP3806858A4 (en) 2018-06-15 2022-03-09 Handa Pharmaceuticals, Inc. SALTS OF KINASE INHIBITORS AND ASSOCIATED COMPOSITIONS
WO2020144647A1 (en) * 2019-01-10 2020-07-16 Aragon Pharmaceuticals, Inc. Pharmaceutical composition comprising apalutamide dispersed in apple sauce
AU2021212258A1 (en) 2020-01-31 2022-09-29 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
CA3181361A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2315043C2 (ru) 2002-06-28 2008-01-20 Ниппон Синяку Ко., Лтд. Амидное производное, фармацевтическая композиция и терапевтические средства на его основе
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
EP1572093B1 (en) * 2002-08-01 2013-04-17 Eisai Inc. Prevention of cancer with glutamine
JP5129123B2 (ja) 2005-05-02 2013-01-23 ノバルティス アーゲー 全身性肥満細胞症の処置のためのピリミジルアミノベンズアミド誘導体の使用
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
KR100925559B1 (ko) * 2007-10-26 2009-11-05 한국과학기술연구원 악티노마이신 ｄ를 유효성분으로 하는 ｄｄｒ과 콜라겐결합 저해제

Also Published As

Publication number Publication date
PL2501384T3 (pl) 2016-08-31
KR20120102635A (ko) 2012-09-18
AR079029A1 (es) 2011-12-21
CN102612368A (zh) 2012-07-25
CA2779490A1 (en) 2011-05-26
MX2012005694A (es) 2012-06-13
RU2625835C2 (ru) 2017-07-19
HUE027307T2 (hu) 2016-10-28
WO2011062927A1 (en) 2011-05-26
JP5829615B2 (ja) 2015-12-09
EP2501384B1 (en) 2016-02-17
CA2779490C (en) 2019-02-12
IL219727A (en) 2016-07-31
TN2012000206A1 (en) 2013-12-12
AU2010322102A1 (en) 2012-05-24
CN102612368B (zh) 2014-03-05
KR101743315B1 (ko) 2017-06-15
FI2501384T4 (fi) 2024-01-11
CO6551690A2 (es) 2012-10-31
RS54747B1 (sr) 2016-10-31
RU2012124811A (ru) 2013-12-27
ES2572128T3 (es) 2016-05-30
SG10201501169VA (en) 2015-04-29
ME02413B (me) 2016-09-20
HRP20160472T4 (hr) 2024-02-02
JP2013511524A (ja) 2013-04-04
GT201200150A (es) 2014-08-11
JO3634B1 (ar) 2020-08-27
SI2501384T1 (sl) 2016-06-30
CL2012001270A1 (es) 2012-10-12
DK2501384T3 (en) 2016-05-17
ZA201203328B (en) 2013-02-27
RS54747B2 (sr) 2024-02-29
PE20121476A1 (es) 2012-11-14
NZ599968A (en) 2014-09-26
SI2501384T2 (sl) 2024-02-29
MY169956A (en) 2019-06-19
DK2501384T4 (da) 2024-01-02
JP2015180636A (ja) 2015-10-15
TWI498116B (zh) 2015-09-01
HK1169950A1 (zh) 2013-02-15
ES2572128T5 (es) 2024-05-17
ECSP12011903A (es) 2012-09-28
EP2501384B2 (en) 2023-11-01
MA33738B1 (fr) 2012-11-01
BR112012011693A2 (pt) 2016-03-01
US20120289528A1 (en) 2012-11-15
IL219727A0 (en) 2012-07-31
TW201141481A (en) 2011-12-01
PL2501384T5 (pl) 2024-01-29
AU2010322102B2 (en) 2014-08-28
HRP20160472T1 (hr) 2016-06-03
EP2501384A1 (en) 2012-09-26
US9061029B2 (en) 2015-06-23

Similar Documents

Publication Publication Date Title
SMT201600143B (it) Metodo di trattamento di disturbi proliferativi e altre condizioni patologiche mediate dalla attività chinasica di bcr-abl, c-kit, ddr1, ddr2 o pdgf-r
IL219109A0 (en) Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity
EP2885419A4 (en) ENZYMES AND POLYMERASES FOR RNA SYNTHESIS
EP3862362A3 (en) Conjugates of modified antisense oligonucleotides and their use for modulating pkk expression
BRPI0916243A2 (pt) suportes ortodônticos e respectivo método de produção
PH12015500114A1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
BR112012001325A2 (pt) tratamento de distúrbios do fígado com inibidaores de pi3k
DK2172241T3 (da) Udbøjeligt kateter med forbundet midterstiver
EP3715457A3 (en) Modulation of prekallikrein (pkk) expression
WO2011090738A3 (en) Type ii raf kinase inhibitors
BRPI1008717A2 (pt) artigos e métodos de tratar condições vasculares.
FI20100385A (fi) Menetelmä ja tuotantolaitos hienojakoisten, mineraalipitoisten kiintoaineiden lämpökäsittelyä varten
DK2451796T3 (da) Tofaanaloger til behandling af dermatologiske lidelser eller tilstande
WO2015017675A3 (en) Methods and compounds useful in conditions related to repeat expansion
WO2012135641A3 (en) Aurora kinase inhibitors and methods of making and using thereof
BR112014004192A2 (pt) composição de tratamento de sementes, e, método de tratamento de sementes
EP2739637A4 (en) DOUBLE-STRONG OLIGONUCLEOTIDE COMPOUNDS FOR THE TREATMENT OF HEARING AND BALANCE OF IMPAIRMENT
BRPI0820440A2 (pt) Inibidores aldh-2 no tratamento de desordens psiquiátricas
SMT201600156B (it) Trattamento dell’osteoartrite
GB2455585B (en) Capsicum seeds for the treatment of eczema and dermatitis
WO2009102438A3 (en) Aptamer inhibitors of osteopontin and methods of use thereof
ITMI20090271A1 (it) Filtro perfezionato e metodo.
DK2656075T3 (da) Fremgangsmåde til optimering af behandlingen af patienter med biologiske lægemidler
TH113426B (th) สารกระจายเชิงประกอบ, วิธีการของการผลิตสารนั้น, และผลิตภัณฑ์ที่ถูกผลิตจากสารนั้น
TH0901004033A (th) อะมิโนไทรแอโซโลพิริดีน, องค์ประกอบของมัน, และวิธีการบำบัดด้วยสารนี้